Equities Analysts Set Expectations for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at Brookline Cap M issued their FY2025 earnings per share estimates for shares of Cardiol Therapeutics in a research report issued on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed expects that the company will post earnings per share of ($0.30) for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Other analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research report on Monday, December 1st. Brookline Capital Acquisition raised Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $9.00.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock traded up $0.03 during trading on Friday, hitting $0.99. 174,245 shares of the stock were exchanged, compared to its average volume of 346,622. The stock’s fifty day moving average is $1.00 and its 200 day moving average is $1.09. Cardiol Therapeutics has a 12 month low of $0.77 and a 12 month high of $1.59. The stock has a market cap of $111.10 million, a PE ratio of -3.32 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.89 and a current ratio of 3.89.

Cardiol Therapeutics (NASDAQ:CRDL) last posted its earnings results on Thursday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09).

Institutional Investors Weigh In On Cardiol Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CRDL. Tejara Capital Ltd boosted its stake in shares of Cardiol Therapeutics by 95.1% during the 4th quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,500,000 shares in the last quarter. Bank of America Corp DE boosted its stake in Cardiol Therapeutics by 1,983.0% in the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock worth $590,000 after purchasing an additional 524,598 shares during the period. Citadel Advisors LLC grew its position in Cardiol Therapeutics by 1,132.6% during the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock worth $496,000 after purchasing an additional 425,862 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cardiol Therapeutics in the third quarter valued at $249,000. Finally, Virtu Financial LLC acquired a new stake in shares of Cardiol Therapeutics in the third quarter worth $154,000. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics News Summary

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CRDL to a “Strong‑Buy,” highlighting bullish analyst sentiment that can spur buying interest from investors and funds. Zacks Upgrade
• Positive Sentiment: Brookline published detailed EPS estimates for 2025–2026 (quarterly losses around $0.07–$0.08; FY2026 forecast ≈ ($0.29)), which are modestly less negative than the consensus FY2026 estimate of ($0.33). The slightly improved outlook vs. consensus can be read as a relative improvement in near‑term expectations. Brookline Estimates
• Neutral Sentiment: Published short‑interest data claims a “large increase” but simultaneously reports 0 shares short and NaN changes, with a days‑to‑cover of 0.0 — the figures look inconsistent and are unlikely to be a meaningful market driver until clarified by reliable data.
• Negative Sentiment: Brookline’s forecasts still show recurring quarterly losses and a negative FY outlook (company remains unprofitable). Ongoing losses limit valuation upside and mean the stock remains sensitive to funding, clinical, or regulatory news. Brookline Estimates

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.